Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Repirinast
Therapeutic Area : Nephrology
Study Phase : Preclinical
Recipient : Algernon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Repirinast was originally developed by Mitsubishi Tanabe Pharma (“Mitsubishi”) and was sold and marketed in Japan under the brand name Romet™ for the treatment of asthma. Romet™ was marketed for over 25 years in Japan.
Brand Name : NP-251
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 23, 2022
Lead Product(s) : Repirinast
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Recipient : Algernon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
